Finally! Shire And Baxalta Sign $32bn Deal To Form Largest Rare Disease Company

11 Jan 2016

• By Sukaina Virji

Shire plc and Baxalta Incorporated have confirmed they are to merge. The combined company, which will be 34% owned by Baxalta shareholders, will be "the partner of choice in rare diseases," claimed Shire CEO Flemming Ornskov.

Finally! Shire And Baxalta Sign $32bn Deal To Form Largest Rare Disease Company

More from Alimentary/Metabolic

More from Therapy Areas